Skip to content
ClinCalc Pro
Menu
Cardiology

CHA₂DS₂-VA Score for AF (ESC 2024)

2024 ESC atrial fibrillation guideline stroke-risk score: CHA₂DS₂-VASc without the sex category. Oral anticoagulation is recommended at a score of 2 or more and should be considered at a score of 1.

Used in: Atrial Fibrillation

Resting BP > 140/90 mmHg or on antihypertensive therapy

Prior MI, peripheral artery disease, or aortic plaque

Score interpretation

CHA₂DS₂-VA 0 — Low Risk 0

No CHA₂DS₂-VA risk factor.

→ Oral anticoagulation is not indicated on the score alone; reassess risk factors regularly.

CHA₂DS₂-VA 1 — Consider Anticoagulation 1

ESC 2024: oral anticoagulation should be considered (Class IIa).

→ Shared decision on anticoagulation; address modifiable bleeding risk factors.

CHA₂DS₂-VA ≥ 2 — Anticoagulation Recommended 2–8

ESC 2024: oral anticoagulation is recommended (Class I).

→ Offer a DOAC in preference to a VKA (VKA for mechanical valves or moderate–severe mitral stenosis); assess and address bleeding risk.

Interpretation bands for the CHA₂DS₂-VA. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

The CHA₂DS₂-VA is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.